Gene Editing Market Scope And Analysis

  • Report Code : TIPRE00032626
  • Category : Biotechnology
  • No. of Pages : 150
Buy Now

Gene Editing Market Scope and Key Players Analysis by 2030

Buy Now


Gene Editing Market Report Scope

Report Attribute Details
Market size in 2022 US$ 6,542.95 Million
Market Size by 2030 US$ 23,902.34 Million
Global CAGR (2022 - 2030) 17.6%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Component
  • Reagents and Consumables
  • Software and Systems
  • Services
By Technology
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Transcription Activator-Like Effector Nucleases
  • Zinc Finger Nucleases
  • Other Technologies
By Application
  • Genetic Engineering and Clinical Applications
By End User
  • Pharmaceutical companies and Biotechnology Companies
  • Academics and Government Research Institutes
  • Clinical Research Organizations
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Thermo Fisher Scientific
  • GenScript
  • Lonza
  • Merck KGaA
  • CRISPR Therapeutics
  • PerkinElmer Inc
  • Agilent Technologies Inc
  • Precision Biosciences
  • Sangamo Therapeutics Inc
  • Industry Developments and Future Opportunities: 

    Various initiatives taken by key players operating in the global gene editing market are listed below:

    • In April 2022, Thermo Fisher Scientific introduced the GMP-manufactured Gibco CTS TrueCut Cas9 Protein to help researchers meet stringent quality requirements while using genome editing tools. It is a promising option for CAR T-cell therapy studies using CRISPR-Cas9 genome editing as it consistently provides higher than 90% efficacy in human primary T-cells and high editing effectiveness in all examined cell lines.

    Competitive Landscape and Key Companies:

    Thermo Fisher Scientific; GenScript; Lonza; Merck KGaA; CRISPR Therapeutics; PerkinElmer Inc.; Agilent Technologies, Inc.; Precision Biosciences; Sangamo Therapeutics, Inc.; New England Biolabs; and Novartis are among the prominent players in the gene editing market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.